Plain-English translation of NCT06110403 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Copd research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing BGF 160 (Trixéo Aerosphere®), an inhaler that combines three medications to help open airways and reduce inflammation in people with COPD. Researchers want to understand exactly how this medication changes your breathing patterns and improves lung function. The study will involve about 35 people with stable COPD who experience shortness of breath.
While combination inhalers are used to treat COPD, scientists still want to understand the detailed ways this medication improves how your lungs work and how you breathe. This research could help doctors better explain to patients why the treatment helps and potentially improve future treatments.
You likely qualify if…
You likely don't qualify if…
You would use the inhaler medication twice daily as prescribed at home. You would visit the research center for several appointments where doctors will perform breathing tests, measure your lung function, ask about your symptoms, and monitor your response to the medication. The study involves specialized breathing measurements and regular check-ins to track how the medication is working for you.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
France
Phase
Safety & dosing / Early efficacy
Sponsor
University Hospital, Lille
Collaborators
AstraZeneca
Enrollment target
~35 participants
Started
September 2023
Primary completion
September 2026
Age range
40 Years – 75 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thierry PEREZ, MD
University Hospital, Lille
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.